Supplementary Table SI. Study investigators.

Region	Investigators
Australia	Dr Stephen Hall; Dr David Nicholls; Dr Maureen Rischmueller.
Canada	Dr Milton F. Baker; Dr Louis Bessette; Dr Alfred A. Cividino; Dr Boulos Haraoui; Dr Henry Niall Jones; Dr Edward C. Keystone; Dr Majed Khraishi; Dr J. Thorne.
United States	Dr Charles Allen Birbara; Dr Herbert Stuart Block Baraf; Dr Joan Marie Bathon; Dr Alan Lawrence Brodsky; Dr John Joseph Cush; Dr Ara Hagop Dikranian; Dr Erdal Diri; Dr Paul Andrew Dura; Dr Kristine Marie Lohr; Dr Roy Mitchell Fleischmann; Dr Robert Michael Griffin Jr.; Dr Dale George Halter; Dr Jody Kay Hargrove; Dr David William Bouda; Dr Suresh Kumar Reddy Pasya; Dr Geneva Louise Hill; Dr Raymond Edward Jackson; Dr Shelly Pearl Kafka; Dr Jeffrey Louis Kaine; Dr Paul L. Katzenstein; Dr Kevin James Kempf; Dr Karen Sue Kolba; Dr Joel Marc Kremer; Dr Selden Longley III; Dr Steven D. Mathews; Dr Ami Charise Milton; Dr Richard James Misischia; Dr Haydon Anthony Moorman; Dr Larry Wayne Moreland; Dr Mark William Niemer; Dr William Rodney Palmer; Dr Michael Eugene Sayers; Dr Patrick Thomas Schuette; Dr Talha Shamim; Dr William Julius Shergy; Dr David Hilton Sikes; Dr Joel Charles Silverfield; Dr Chokkalingam Siva; Dr James D. Taborn; Dr Bridget Tyrell Walsh; Dr Alvin Francis Wells; Dr Sanford Mayer Wolfe.
Asia	Dr Prabha Adhikari, India; Dr Kouichi Amano, Japan; Dr Sang-Cheol Bae, Korea; Dr Srikantiah Chandrashekara, India; Dr Arvind K Chopra, India; Dr Ping-Ning Hsu, Taiwan; Dr Mitsuhiro Iwahashi, Japan; Dr Jugal Kishore Kadel, India; Dr Yojiro Kawabe, Japan; Dr Eun-Mi Koh, Korea; Dr Joung-liang Lan, Taiwan; Dr Soo-Kon Lee, Korea; Dr Hsiao-Yi Lin, Taiwan; Dr Lieh-bang Liou, Taiwan; Dr Ming-Fei Liu, Taiwan; Dr Kiyoshi Migita, Japan; Dr Toshiaki Miyamoto, Japan; Dr Nobuyuki Miyasaka, Japan; Dr Shunsuke Mori, Japan; Dr Yasuhiko Munakata, Japan; Dr Shuji Ohta, Japan; Dr Won Park, Korea; Dr Sung-Hwan Park, Korea; Dr Uppuluri Ramakrishna Rao, India; Dr Seung Cheol Shim, Korea; Dr Vineeta Shobha, India; Dr Yeong-Wook Song, Korea; Dr Yoshinari Takasaki, Japan; Dr Tsutomu Takeuchi, Japan; Dr Yoshiya Tanaka, Japan; Dr Shigeto Tohma, Japan; Dr Wen-Chan Tsai, Taiwan; Dr Yukitaka Ueki, Japan; Dr Sarath Chandra Mouli Veeravalli, India; Dr Shrikant Wagh, India; Dr Hisashi Yamanaka, Japan; Dr Bin Yoo, Korea.
Europe	Dr Anastas Batalov, Bulgaria; Dr Daniela Bichoversuska, Bulgaria; Dr Zdenek Dvorak, Czech Republic; Dr Ivan Goranov, Bulgaria; Dr Halyna M. Hrytsenko, Ukraine; Dr Jana Kopackova, Czech Republic; Dr Zdenka Mosterova, Czech Republic; Dr Boycho Oparanov, Bulgaria; Dr Andriy Petrov, Ukraine; Dr Ines Pokrzywnicka-Gajek, Poland; Prof. Vladyslav V. Povoroznyuk, Ukraine; Dr Jan Rosa, Czech Republic; Dr Zofia Ruzga, Poland; Prof. Loukas Settas, Greece; Prof. Mykola A. Stanislavchuk, Ukraine; Dr Dana Tegzová, Czech Republic; Dr Vira Iosypivna Tseluyko, Ukraine; Dr Petr Vitek, Czech Republic.
Latin America	Dr Cristiano Augusto de Freitas Zerbini, Brazil; Dr Joao Carlos Tavares Brenol, Brazil; Dr Mario H. Cardiel-Rios, Mexico; Dr William Jose Otero Escalante, Colombia; Dr Maria Concepcion Maldonado-Lopez, Colombia; Dr Juan Jose Jaller Raad, Colombia; Dr Javier Dario Marquez Hernandez MD, Colombia; Dr Edwin Antonio Jauregui, Colombia; Dr Mauro W. Keiserman, Brazil; Dr Ana Claudia Cauceglia Melazzi, Brazil; Dr Virginia Pascual-Ramos, Mexico; Dr Luciana Teixeira Pinto, Brazil; Dr Sebastiao C. Radominski, Brazil; Dr Antonio Carlos Ximenes, Brazil; Dr Sol Villegas de Morales, Venezuela.



Suppl. Fig. 1. Patient disposition through to month 24.
All patients received background methotrexate, including those in the placebo groups.
Additional details of patient disposition in this study are available in VAN DER HEIJDE D, STRAND V, TANAKA Y, KEYSTONE E, KREMER J, ZERBINI CAF *et al*.: Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic and safety outcomes from the 24-month Phase 3 ORAL Scan study. *Arthritis Rheum* 2019; 71: 878-89.
[a]JCI <20% from baseline at Month 3, n=84 (26%); [b]JCI <20% from baseline at Month 3, n=56 (18%); [c]JCI <20% from baseline at Month 3, n=42 (52%); [d]JCI <20% from baseline at Month 3, n=37 (47%).
AE: adverse event; BID: twice daily; JCI: joint count improvement.



Suppl. Fig. 2. Rates of HAQ-DI **(A)** normative (≤0.25) and **(B)** functional remission (<0.5) scores, by treatment sequence through Month 24.
All patients initially receiving placebo had advanced to tofacitinib by Month 6, shown with a grey line.
BID: twice daily; HAQ-DI, Health Assessment Questionnaire-Disability Index.